Lyra Therapeutics (LYRA) Stock Statistics & Valuation Metrics

Lyra Therapeutics has a market cap or net worth of $10.44M. The enterprise value is $14.78M.

Lyra Therapeutics has 1,644,454 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lyra Therapeutics’s return on equity (ROE) is -8.06 and return on invested capital (ROIC) is -166.66%.

The current PE Ratio of Lyra Therapeutics is ―. Lyra Therapeutics’s PEG ratio is ―.

In the last 12 months, Lyra Therapeutics had revenue of 1.53M and earned -93.44M in profits. Earnings per share was -1.43.

In the last 12 months, operating cash flow was -43.01M and capital expenditures -13.00K, giving a free cash flow of -43.02M billion.

Lyra Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Lyra Therapeutics upcoming earnings date is Nov 11, 2025, After Close (Confirmed).

Lyra Therapeutics as a current ratio of 3.41, with Debt / Equity ratio of 2002.34%

In the past 12 months, Lyra Therapeutics has paid 39.00K in taxes.

Lyra Therapeutics EV to EBITDA ratio is -11.05, with an EV/FCF ratio of -9.20.

Lyra Therapeutics has $29.78M in cash and marketable securities with $32.48M in debt, giving a net cash position of -$2.69M billion.

Gross margin is 76.23%, with operating margin of -6280.83%, and net profit margin of -6090.94%.

The average price target for Lyra Therapeutics is $16.00, which is 11.43% higher than the current price. The consensus rating is Hold